Related Experiment Video
Updated: Oct 12, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Outcomes of hypertrophic cardiomyopathy in Japanese children: a retrospective cohort study
Hiroki Mori1, Tadahiro Yoshikawa2, Hitomi Kimura2
1Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Insights
Pediatric hypertrophic cardiomyopathy (HCM) in Japan has a good long-term survival rate, with 80% of patients surviving 20 years. Heart failure symptoms and cardiothoracic ratio predict heart failure-related death in pediatric HCM.
Area of Science:
- Cardiology
- Pediatric Medicine
- Genetics
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease.
- Pediatric HCM prognosis data is limited, especially from multicenter studies in Japan.
Purpose of the Study:
- To evaluate the long-term survival rate and identify risk factors for pediatric hypertrophic cardiomyopathy (HCM) in Japan.
- To provide crucial data for managing pediatric HCM patients.
Main Methods:
- Retrospective multicenter observational study.
- Involved 20 institutions and 180 patients diagnosed with HCM under 18 years old (1990-2014).
- Analyzed survival rates, causes of death, and risk factors.
Main Results:
- Long-term survival rates at 1, 5, 10, and 20 years were 97%, 92%, 84%, and 80%, respectively.
- 26 deaths occurred: 11 sudden (arrhythmia) and 15 heart failure-related.
- Heart failure symptoms and higher cardiothoracic ratio were significant risk factors for heart failure-related death.
Conclusions:
- The prognosis for pediatric hypertrophic cardiomyopathy in Japan is favorable and comparable to international studies.
- Identified key risk factors for heart failure-related mortality in this population.
- Further research is needed to identify risk factors for arrhythmia-related death.
Abstract:
There has been no multicenter study on the prognosis of pediatric hypertrophic cardiomyopathy (HCM) in Japan. Therefore, we conducted a retrospective multicenter observational study on the long-term survival rate in patients diagnosed with HCM under the age of 18 between 1990 and 2014. Twenty institutions participated. A total of 180 patients were identified. The median age at diagnosis was 5.8 years old and median duration of observation was 8.3 years. Although six patients (3%) deteriorated into the dilated phase of HCM, no patient received heart transplantation. Freedom from death at 1, 5, 10, and 20 years were 97%, 92%, 84%, and 80%, respectively. There were 26 deaths. Among them, 11 patients died suddenly, presumably due to arrhythmia, and 15 patients died of heart failure. The presence of heart failure symptoms and a greater cardiothoracic ratio were significant risk factors for heart failure-related death. There were no significant risk factors identified for arrhythmia-related death. In conclusion, the prognosis of pediatric HCM in Japan is good and similar to those reported in population-based studies in the United States and Australia. Significant risk factors for heart failure-related death were identified in pediatric patients with HCM in Japan.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy I: Introduction and Classification

